NM_001013251.3(SLC3A2):c.1320C>A (p.Phe440Leu) AND not specified

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Mar 25, 2024
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV004683750.1

Allele description [Variation Report for NM_001013251.3(SLC3A2):c.1320C>A (p.Phe440Leu)]

NM_001013251.3(SLC3A2):c.1320C>A (p.Phe440Leu)

Gene:

SLC3A2:solute carrier family 3 member 2 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

11q12.3

Genomic location:

Preferred name:

NM_001013251.3(SLC3A2):c.1320C>A (p.Phe440Leu)

HGVS:

NC_000011.10:g.62888423C>A
NM_001012662.3:c.1626C>A
NM_001012664.3:c.1437C>A
NM_001013251.3:c.1320C>AMANE SELECT
NM_002394.6:c.1623C>A
NP_001012680.1:p.Phe542Leu
NP_001012682.1:p.Phe479Leu
NP_001013269.1:p.Phe440Leu
NP_002385.3:p.Phe541Leu
NC_000011.9:g.62655895C>A
NM_001012662.2:c.1626C>A
NR_037193.2:n.1214C>A

Protein change:

F440L

Molecular consequence:

NM_001012662.3:c.1626C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001012664.3:c.1437C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001013251.3:c.1320C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_002394.6:c.1623C>A - missense variant - [Sequence Ontology: SO:0001583]
NR_037193.2:n.1214C>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Synonyms:: AllHighlyPenetrant
Identifiers:: MedGen: CN169374

Recent activity

Clear Turn Off Turn On

PREDICTED: Mus musculus epididymal protein 13 (Eddm13), transcript variant X4, m...
PREDICTED: Mus musculus epididymal protein 13 (Eddm13), transcript variant X4, mRNA
gi|1039779571|ref|XM_006540265.3|

Nucleotide

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV005168921	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (Mar 25, 2024)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV005168921

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(Mar 25, 2024)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV005168921.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The c.1626C>A (p.F542L) alteration is located in exon 12 (coding exon 12) of the SLC3A2 gene. This alteration results from a C to A substitution at nucleotide position 1626, causing the phenylalanine (F) at amino acid position 542 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Aug 11, 2024

ClinVar

Relating variation to medicine